NDAINJECTIONINJECTABLE
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPECTAMINE (Iofetamine Hydrochloride I-123) is a radiopharmaceutical injectable diagnostic agent approved in 1987 for brain imaging. It is used as a single-photon emission computed tomography (SPECT) agent to assess cerebral blood flow and evaluate neurological conditions. The drug works by accumulating in brain tissue proportional to regional cerebral perfusion.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely in defensive/transition mode with limited hiring for growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No linked job openings are currently available for SPECTAMINE, reflecting the product's mature LOE-approaching status. Career opportunities on this product are limited to market maintenance roles rather than growth or innovation positions.
Field SalesBrand Manager
Worked on SPECTAMINE at Amneal Pharms? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.